Eric Topol
In cognitively intact people, the level of p-tau217 in the blood tells us about the risk and timing for developing cognitive impairment and Alzheimer's disease. A new study indicates the additive effect of APOE4 carrier status on risk and timing. "Each 1-SD increase in p-tau217 concentration was associated with a 24% shorter time to cognitive impairment among APOE-ε4 carriers, compared with 13% among non-carriers." https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00313-3/fulltext